Novartis dials down RNA research

Share this article:

Novartis is scaling down its push to develop RNA therapies. BioCentury reports that the drugmaker plans to “maintain a small group in the field and will look into partnering opportunities” but will “significantly reduce” its internal focus.

According to BioCentury, the drugmaker said RNA treatments look to be a narrow field and that the company expects to lay off some of the 26 employees dedicated to RNA research.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.